Loading
A phase 3 trial of Ivonescimab, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by Akeso, now recruiting.
Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06928389 by Akeso, with 536 participants planned, started 2025-07-08 and due to reach its primary completion in 2027-05. Interventions recorded: Ivonescimab, docetaxel, Placebo, docetaxel. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Akeso, Ivonescimab, Bispecific antibodies, Small-cell lung cancer.
Shares Akeso, Ivonescimab, Bispecific antibodies, Docetaxel.
Shares Akeso, Ivonescimab, Bispecific antibodies, Docetaxel.
Shares Akeso, Ivonescimab, Bispecific antibodies, Small-cell lung cancer.
Shares Akeso, Ivonescimab, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Akeso, Ivonescimab, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Akeso, Ivonescimab, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Ivonescimab, Bispecific antibodies, Small-cell lung cancer, Immune checkpoint inhibitors.